# ALLO (Allogene Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Allogene Therapeutics, Inc. reported $0 in revenue and a net loss of $174.5M for the fiscal year ended December 31, 2025 (down 100.0% year over year).

- Canonical: https://convexityos.com/fundamentals/ALLO
- Markdown: https://convexityos.com/fundamentals/ALLO.md
- SEC CIK: 0001737287
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:39 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001737287&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $0 | -100.0% YoY |
| Operating Income | FY 2025 | -$190.2M | Operating profit |
| Net Income | FY 2025 | -$174.5M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.50 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$108.8M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $293.0M | Total debt: $76.94M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $22K | $95K | $156K | $114.1M | $0 | $0 | -- |
| Research & Development | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M | $151.9M |
| Total Operating Expenses | $209.3M | $273.2M | $327.8M | $335.7M | $294.3M | $258.2M | $202.0M | $192.8M |
| **Operating Income** | -$209.3M | -$273.2M | -$327.7M | -$335.5M | -$180.2M | -$258.2M | -$202.0M | -$192.8M |
| **EBITDA** | -$197.0M | -$259.6M | -$313.5M | -$321.2M | -$169.7M | -$250.8M | -$197.4M | -$191.8M |
| Interest Expense | $1.07M | $181K | $0 | -- | -- | $0 | $0 | $3.36M |
| Income Before Tax | -$190.9M | -$257.1M | -$327.3M | -- | -$257.0M | -$250.2M | -$184.9M | -$211.6M |
| Income Tax Expense | $0 | $443K | $0 | $0 | $0 | $0 | -$331K | -$117K |
| **Net Income** | -$190.9M | -$257.6M | -$327.3M | -$340.4M | -$182.1M | -$250.2M | -$184.6M | -$211.5M |
| Basic EPS | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.08 | -$1.83 | -$7.31 |
| **Diluted EPS** | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.08 | -$1.83 | -$7.31 |
| Basic Shares Outstanding | 220.6M | 194.8M | 156.9M | 143.1M | 135.8M | 120.4M | 101.1M | 28.9M |
| Diluted Shares Outstanding | 220.6M | 194.8M | 156.9M | 143.1M | 135.8M | 120.4M | 101.1M | 28.9M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $4.64M | -- | $0 | $0 | $0 | $0 | $0 |
| Research & Development | $41.93M | $30.72M | $32.00M | $28.63M | $31.16M | $40.16M | $50.20M | $44.97M |
| Total Operating Expenses | $54.79M | $51.56M | $46.09M | $42.40M | $44.90M | $56.82M | $65.19M | $60.49M |
| **Operating Income** | -$54.79M | -$46.92M | -$46.09M | -$42.40M | -$44.90M | -$56.82M | -$65.19M | -$60.49M |
| **EBITDA** | -$52.21M | -$44.27M | -$43.22M | -$39.35M | -$41.80M | -$53.71M | -$62.09M | -$57.26M |
| Interest Expense | $379K | $343K | $300K | $313K | $344K | $268K | $150K | $81K |
| **Net Income** | -$50.37M | -$42.68M | -$42.61M | -$38.81M | -$41.40M | -$50.94M | -$59.73M | -$59.94M |
| Basic EPS | -$0.15 | -$0.13 | -$0.18 | -- | -$0.19 | -$0.23 | -$0.28 | -- |
| **Diluted EPS** | -$0.15 | -$0.13 | -$0.18 | -- | -$0.19 | -$0.23 | -$0.28 | -- |
| Basic Shares Outstanding | 346.1M | 328.9M | 240.3M | -- | 222.0M | 218.9M | 215.4M | -- |
| Diluted Shares Outstanding | 346.1M | 328.9M | 240.3M | -- | 222.0M | 218.9M | 215.4M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2022 | FY 2022 | FY 2022 | FY 2022 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $51.69M | $75.22M | $83.16M | $69.25M | $154.8M | $109.9M | $61.90M | $74.36M | $96.04M | $84.51M |
| Short-Term Investments | $198.5M | $217.3M | $365.5M | $396.3M | $337.2M | $361.3M | $455.4M | $477.9M | $394.5M | $364.5M |
| **Cash & Short-Term Investments** | $258.3M | $373.1M | $448.7M | $497.7M | $544.5M | $514.0M | $576.5M | $637.3M | $686.1M | $733.1M |
| **Total Current Assets** | $257.7M | $303.4M | $459.1M | $473.5M | $502.1M | $481.5M | $528.8M | $569.1M | $513.0M | $469.7M |
| Property, Plant & Equipment, Net | $72.84M | $86.06M | $99.48M | $102.8M | $106.4M | $109.8M | $112.8M | $114.4M | $117.2M | $120.2M |
| Long-Term Investments | $8.04M | $80.67M | $0 | $32.17M | $52.59M | $42.79M | $59.15M | $85.11M | $195.6M | $284.1M |
| Other Non-Current Assets | $3.62M | $2.33M | $6.60M | $9.58M | $9.38M | $9.39M | $9.56M | $9.38M | $8.94M | $9.04M |
| **Total Non-Current Assets** | $158.2M | $245.3M | $183.7M | $240.0M | $270.9M | $268.7M | $292.8M | $325.4M | $442.6M | $508.3M |
| **Total Assets** | $415.9M | $548.7M | $642.8M | $713.4M | $773.0M | $750.1M | $821.6M | $894.5M | $955.6M | $978.1M |
| Accounts Payable | $4.27M | $5.39M | $5.90M | $6.21M | $10.23M | $14.69M | $13.89M | $11.04M | $9.71M | $8.71M |
| Deferred Revenue (Current) | -- | -- | $86K | $86K | $86K | $86K | $95K | $99K | $104K | $147K |
| Other Current Liabilities | $2.40M | $1.07M | $1.81M | -- | -- | -- | $2.12M | -- | -- | -- |
| **Total Current Liabilities** | $32.51M | $35.52M | $37.08M | $37.49M | $54.58M | $59.40M | $53.73M | $48.08M | $44.18M | $36.62M |
| Other Non-Current Liabilities | $15.80M | $7.76M | $5.18M | $5.19M | $5.20M | $5.21M | $5.85M | $6.29M | $6.73M | $7.17M |
| **Total Non-Current Liabilities** | $90.85M | $91.01M | $93.53M | $95.29M | $97.02M | $98.72M | $101.0M | $103.0M | $105.0M | $76.20M |
| **Total Liabilities** | $123.4M | $126.5M | $130.6M | $132.8M | $151.6M | $158.1M | $154.7M | $151.1M | $149.1M | $112.8M |
| **Total Debt (incl. Leases)** | $83.25M | $90.76M | $95.12M | $96.68M | $98.20M | $99.70M | $101.1M | $102.5M | $103.6M | $72.62M |
| Common Stock | $229K | $212K | $169K | $168K | $167K | $146K | $144K | $144K | $144K | $143K |
| Retained Earnings | -$2.01B | -$1.82B | -$1.56B | -$1.48B | -$1.41B | -$1.33B | -$1.23B | -$1.14B | -$1.05B | -$973.2M |
| Accumulated Other Comp. Income | $269K | -$89K | -$955K | -$2.41M | -$3.85M | -$5.93M | -$9.93M | -$12.96M | -$11.47M | -$9.25M |
| **Total Stockholders' Equity** | $292.5M | $422.2M | $512.2M | $580.6M | $621.4M | $592.0M | $666.9M | $743.4M | $806.5M | $865.3M |
| Total Equity | $292.5M | $422.2M | $512.2M | $580.6M | $621.4M | $592.0M | $666.9M | $743.4M | $806.5M | $865.3M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $29.27M | $38.63M | $30.31M | $51.69M | $37.81M | $52.33M | $42.45M | $75.22M |
| Short-Term Investments | $263.7M | $294.0M | $236.6M | $198.5M | $214.4M | $220.8M | $237.6M | $217.3M |
| **Cash & Short-Term Investments** | $388.9M | $423.6M | $266.9M | $258.3M | $277.1M | $302.6M | $335.5M | $373.1M |
| **Total Current Assets** | $299.8M | $340.0M | $273.3M | $257.7M | $260.7M | $282.7M | $291.6M | $303.4M |
| Property, Plant & Equipment, Net | $64.82M | $67.38M | $70.02M | $72.84M | $75.90M | $78.86M | $82.99M | $86.06M |
| Long-Term Investments | $95.92M | $90.99M | $0 | $8.04M | $24.94M | $29.51M | $55.51M | $80.67M |
| Other Non-Current Assets | $3.82M | $3.69M | $3.53M | $3.62M | $3.51M | $3.83M | $1.90M | $2.33M |
| **Total Non-Current Assets** | $211.5M | $210.1M | $122.7M | $158.2M | $179.1M | $187.9M | $216.4M | $245.3M |
| **Total Assets** | $511.3M | $550.1M | $396.0M | $415.9M | $439.8M | $470.6M | $508.0M | $548.7M |
| Accounts Payable | $8.78M | $5.96M | $4.93M | $4.27M | $3.70M | $4.85M | $5.06M | $5.39M |
| Other Current Liabilities | -- | -- | -- | $2.40M | -- | -- | -- | $1.07M |
| **Total Current Liabilities** | $38.50M | $31.73M | $28.33M | $32.51M | $31.83M | $31.68M | $30.02M | $35.52M |
| Other Non-Current Liabilities | $12.23M | $11.84M | $16.12M | $15.80M | $15.47M | $15.12M | $11.28M | $7.76M |
| **Total Non-Current Liabilities** | $80.27M | $82.19M | $88.75M | $90.85M | $92.61M | $94.36M | $92.57M | $91.01M |
| **Total Liabilities** | $118.8M | $113.9M | $117.1M | $123.4M | $124.4M | $126.0M | $122.6M | $126.5M |
| **Total Debt (incl. Leases)** | $76.94M | $79.01M | $81.05M | $83.25M | $85.14M | $87.00M | $88.92M | $90.76M |
| Common Stock | $346K | $345K | $245K | $229K | $223K | $220K | $219K | $212K |
| Retained Earnings | -$2.15B | -$2.10B | -$2.05B | -$2.01B | -$1.97B | -$1.93B | -$1.88B | -$1.82B |
| Accumulated Other Comp. Income | -$1.44M | -$518K | -$183K | $269K | $235K | -$45K | $43K | -$89K |
| **Total Stockholders' Equity** | $392.6M | $436.2M | $278.9M | $292.5M | $315.3M | $344.6M | $385.4M | $422.2M |
| Total Equity | $392.6M | $436.2M | $278.9M | $292.5M | $315.3M | $344.6M | $385.4M | $422.2M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$190.9M | -$257.6M | -$327.3M | -$340.4M | -$182.1M | -$250.2M | -$184.6M | -$211.5M |
| Depreciation & Amortization | $12.36M | $13.64M | $14.20M | $14.30M | $10.50M | $7.40M | $4.60M | $1.00M |
| Stock-Based Compensation | $37.64M | $51.74M | $65.95M | $83.60M | $80.82M | $65.26M | $46.06M | $18.57M |
| Change in Payables | -$1.23M | -$503K | -$7.50M | $4.87M | -$767K | $615K | -$985K | $8.80M |
| **Operating Cash Flow** | -$149.2M | -$200.3M | -$237.7M | -$220.5M | -$184.8M | -$115.1M | -$137.3M | -$44.65M |
| Capital Expenditure | -$386K | -$694K | -$1.52M | -$5.19M | -$21.45M | -$65.96M | -$50.79M | -$3.23M |
| **Free Cash Flow** | -$149.6M | -$201.0M | -$239.2M | -$225.7M | -$206.3M | -$181.1M | -$188.1M | -$47.89M |
| Purchases of Investments | -$138.3M | -$361.5M | -$438.6M | -$248.1M | -$525.6M | -$1.04B | -$252.6M | -$649.3M |
| Sales & Maturities of Investments | $234.2M | $437.9M | $603.4M | $359.5M | $728.4M | -- | -- | -- |
| **Investing Cash Flow** | $95.56M | $75.69M | $163.3M | $106.2M | $163.7M | -$505.1M | $164.1M | -$632.8M |
| Common Stock Issued | -- | -- | $91.11M | $0 | $0 | $595.7M | $0 | $343.7M |
| **Financing Cash Flow** | $30.16M | $116.7M | $95.69M | $2.95M | $11.96M | $633.6M | $58.96M | $771.2M |
| **Net Change in Cash** | -$23.53M | -$7.94M | $21.25M | -$111.4M | -$9.19M | $13.38M | $85.69M | $93.73M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$50.37M | -$42.68M | -$42.61M | -$38.81M | -$41.40M | -$50.94M | -$59.73M | -$59.94M |
| Depreciation & Amortization | $2.59M | $2.65M | $2.87M | $3.06M | $3.10M | $3.11M | $3.10M | $3.23M |
| Stock-Based Compensation | $7.03M | $12.44M | $8.27M | $8.13M | $8.65M | $8.69M | $12.18M | $12.87M |
| Change in Payables | $2.81M | $1.03M | $663K | $599K | -$1.07M | -$422K | -$336K | $34K |
| **Operating Cash Flow** | -$36.12M | -$32.00M | -$12.91M | -$27.60M | -$29.69M | -$39.03M | -$52.93M | -$36.70M |
| Capital Expenditure | -$25K | -$150K | -$9.0K | $0 | -$243K | -$44K | -$99K | -$257K |
| **Free Cash Flow** | -$36.14M | -$32.15M | -$12.92M | -$27.60M | -$29.93M | -$39.07M | -$53.03M | -$36.95M |
| Purchases of Investments | -$46.06M | -$183.7M | -$101.7M | -$28.38M | -$49.73M | -$9.92M | -$50.23M | -$46.97M |
| Sales & Maturities of Investments | -- | -- | -- | -- | -- | -- | -- | $102.2M |
| **Investing Cash Flow** | $26.12M | -$147.6M | -$29.59M | $33.61M | $11.94M | $43.84M | $6.18M | $54.93M |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | $10.00M | -- |
| **Financing Cash Flow** | $646K | $187.9M | $21.12M | $7.86M | $3.24M | $5.07M | $13.99M | $5.74M |
| **Net Change in Cash** | -$9.36M | $8.32M | -$21.38M | $13.87M | -$14.52M | $9.88M | -$32.76M | $23.98M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -1241813.6% | -344986.3% | -215087.2% | -157.9% | -- | -- | -- |
| **Net Profit Margin** | -- | -1170863.6% | -344489.5% | -218214.1% | -159.6% | -- | -- | -- |
| Return on Equity (ROE) | -65.3% | -61.0% | -63.9% | -51.0% | -19.7% | -24.7% | -29.3% | -30.1% |
| Return on Assets (ROA) | -45.9% | -46.9% | -50.9% | -41.4% | -17.5% | -20.4% | -25.7% | -27.3% |
| Current Ratio | 7.93x | 8.54x | 12.38x | 9.84x | 9.78x | 8.96x | 16.46x | 15.89x |
| Quick Ratio | 7.94x | 10.50x | 12.10x | 10.73x | 16.80x | 10.60x | 17.80x | 24.49x |
| Debt to Equity | 0.28x | 0.21x | 0.19x | 0.15x | 0.08x | 0.05x | 0.08x | 0.05x |
| **Revenue Growth (YoY)** | -100.0% | -76.8% | -39.1% | -99.9% | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -- | -- | -- | -- | -1241813.6% |
| **Net Profit Margin** | -- | -- | -- | -- | -- | -- | -- | -1170863.6% |
| Return on Equity (ROE) | -44.4% | -37.9% | -62.3% | -65.3% | -67.2% | -68.8% | -65.5% | -61.0% |
| Return on Assets (ROA) | -34.1% | -30.1% | -43.9% | -45.9% | -48.2% | -50.3% | -49.7% | -46.9% |
| Current Ratio | 7.79x | 10.72x | 9.65x | 7.93x | 8.19x | 8.92x | 9.71x | 8.54x |
| Quick Ratio | 10.10x | 13.35x | 9.42x | 7.94x | 8.70x | 9.55x | 11.18x | 10.50x |
| Debt to Equity | 0.20x | 0.18x | 0.29x | 0.28x | 0.27x | 0.25x | 0.23x | 0.21x |
| **Revenue Growth (YoY)** | -- | -- | -- | -- | -- | -- | -100.0% | -100.0% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
